Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic functional constipation according to Rome III criteria~* No stool softeners therapy administered during the 7 days prior to Baseline Visit~* Signature of informed consent from by both parents or legal representative~* Willingness to follow the study schedule~Exclusion Criteria:~* Suspicious or established diagnosis of organic constipation~* Delayed emission of meconium in the term newborn~* Presence of severe inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), toxic megacolon~* Presence/Risk of gastroinstestinal perforation~* Presence/Suspiceous intestinal obstruction of symptomatic stenosis~* (Undeterminated) Abdominal pain~* Hypersensitivity to macrogol (polyethylene glycol) or to one or more product excipients~* Hereditary fructose intolerance~* Known hypersensitivity or allergy to any Promelaxin component~* Presence of any other medical condition that contraindicate the use of Promelaxin® or Macrogol 4000

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- micro-enema with Promelaxin (Type: EXPERIMENTAL): 2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
- Macrogol 4000 (Type: ACTIVE_COMPARATOR): One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).

Based on this trial design, predict the completion outcome and termination type (if applicable).